Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.91
-4.96 (-3.52%)
Streaming Delayed Price
Updated: 3:26 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
54
55
Next >
Why Novo Nordisk Stock Is Surging Higher Today
November 02, 2023
The drugmaker's type 2 diabetes and weight-loss treatment is a growth powerhouse.
Via
The Motley Fool
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
November 02, 2023
NVO earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Wegovy Maker Novo Nordisk's Obesity, Diabetes Drug Sales Hit Whopping $22B In Nine Months, Prepares To Expand Capacity
November 02, 2023
Novo Nordisk A/S's (NYSE: NVO) sales for Q3 FY23 climbed 29% Y/Y to DKK
Via
Benzinga
Novo Nordisk Stock Jumps As Wegovy Sales Skyrocket 734%, Crushing Expectations
November 02, 2023
The company's weight-loss drug beat expectations, though sales of diabetes shot Ozempic came in light.
Via
Investor's Business Daily
Weight Watchers Q3 Earnings Preview: Will Ozempic Weigh Down WW Stock?
November 02, 2023
Weight Watchers stock, trading as WW, is already down 30% YTD. Here's what analysts will be watching in the Q3 earnings report.
Via
Benzinga
7 A-Rated Tech Stocks to Buy for November
November 02, 2023
By investing in tech stocks, investors can capitalize on groundbreaking technological advancements and be a part of the future.
Via
InvestorPlace
Earnings Preview For Novo Nordisk
November 01, 2023
Via
Benzinga
Novo Nordisk Unusual Options Activity For October 30
October 30, 2023
Via
Benzinga
Looking At Novo Nordisk's Recent Unusual Options Activity
October 26, 2023
Via
Benzinga
'AI' Crowned 2023's Word Of The Year, Nudges Out Greedflation, Deinfluencing
November 01, 2023
AI is named the word of the year by a leading dictionary. Find out why and what other words almost beat it.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
November 01, 2023
McKesson earnings are on tap, with Cencora and Cardinal Health due soon.
Via
Investor's Business Daily
These Foods Have An Ozempic-Like Effect And Could Help You Lose Weight
November 01, 2023
GLP-1s, or weight-loss drugs like Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy, are helping millions of Americans manage their weight and diabetes.
Via
Benzinga
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Ozempic Supply Is Running Low: Here's Why That Can Be A Problem
October 31, 2023
Ozempic, the diabetes drug also used as a so-called "miracle" weight-loss drug, has been sweeping through America and is now in limited supply.
Via
Benzinga
(NVO) - Analyzing Novo Nordisk's Short Interest
October 24, 2023
Via
Benzinga
1 Green Flag and 1 Red Flag for Novo Nordisk
October 24, 2023
Even this high-flying company has its detractors.
Via
The Motley Fool
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
October 31, 2023
Viatris now faces a narrower path to commercializing a generic copy of Ozempic.
Via
The Motley Fool
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
October 29, 2023
Novo Nordisk is planting the seeds to become a competitor in chronic kidney disease therapies.
Via
The Motley Fool
Benzinga Bulls And Bears: Tesla, Chevron, Eli Lilly And Dogecoin Co-founder's 3 Favorite Cryptos
October 28, 2023
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
October 27, 2023
Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such...
Via
Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
October 27, 2023
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story.
Via
Investor's Business Daily
3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K
October 27, 2023
These are three growth stocks you will want to buy and never sell if you have $1,000 available to invest today.
Via
InvestorPlace
Weight Loss Drugs Like Wegovy Would Not Impact Business - Healthcare Companies Tell Investors
October 27, 2023
Novo Nordisk A/S (NYSE: NVO) investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply limitations for its weight-loss drug, Wegovy, in the U.S.
Via
Benzinga
Q3 Earnings Season Scorecard - Earnings Growth Turns Positive
October 26, 2023
The Q3 revenue beats percentage of 63.2% is the lowest since the 61.7% for this group of companies in 2020 Q1.
Via
Talk Markets
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
October 26, 2023
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy.
Via
Benzinga
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
October 25, 2023
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.
October 25, 2023
Employers could help bolster demand for weight-loss treatments.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
October 24, 2023
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.